| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444645 | European Journal of Cancer | 2013 | 10 Pages |
Abstract
This randomised non-comparative study demonstrates that bevacizumab-XELIRI and bevacizumab-FOLFIRI are effective regimens for the first-line treatment of patients with mCRC with manageable toxicity profiles.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M. Ducreux, A. Adenis, J.-P. Pignon, E. François, B. Chauffert, J.L. Ichanté, E. Boucher, M. Ychou, J.-Y. Pierga, C. Montoto-Grillot, T. Conroy,